膀胱肿瘤复发和进展评分对非肌层浸润性膀胱肿瘤预后的判断价值

发布时间：2018-06-05 03:53

本文选题：非肌层浸润性膀胱肿瘤 + 　；参考：《中国老年学杂志》2015年10期

【摘要】：目的探讨非肌层浸润性膀胱肿瘤术后复发和进展评分对预测其患者预后的临床价值。方法依据非肌层浸润性膀胱肿瘤术后复发和进展危险评分系统(EORTC)对2005年4月至2009年9月该院收治的131例非肌层浸润性膀胱肿瘤患者术后进行评分,并计算各评分等级组术后患者的1、3、5年复发率和进展率。结果依据复发评分计算后分为0分组、1~4分组、5~9分组和10~17分组,其中患者术后1、3、5年复发率与欧洲膀胱治疗研究组织(EORTC)评分预测的参照复发比较无显著差异(P0.05);依据进展评分计算后分为0分组、2~6分组、7~13分组、14~23分组,其中患者术后1、3、5年进展率与EORTC评分预测的进展率比较无显著差异(P0.05)。结论根据非肌层浸润性膀胱肿瘤患者术后评分实际情况将其分为不同评分等级,对患者预测1~5年的预后具有重要的临床意义,但目前有待多中心、大样本临床试验进一步验证。
[Abstract]:Objective to evaluate the clinical value of non-myometrial invasive bladder tumor recurrence and progression score in predicting the prognosis. Methods 131 patients with non-myometrial invasive bladder tumor who were treated in our hospital from April 2005 to September 2009 were evaluated according to the risk of recurrence and progression of non-muscular invasive bladder tumor. The recurrence rate and progression rate of each grade group were calculated. Results according to the recurrence score, the patients were divided into 0, 1, 4, 5, 9, and 10, 17 groups, respectively. Among them, there was no significant difference between the recurrence rate of 3 and 5 years after operation and the reference recurrence predicted by the European bladder treatment Research Organization (EORTC) score (P 0.05), and the patients were divided into 0 group, 2 group, 7 group, 13 group and 14 23 group, according to the progress score, there was no significant difference between them. There was no significant difference in the rate of progression between 3 and 5 years after operation and that predicted by EORTC score (P 0.05). Conclusion according to the actual situation of non-myometrial invasive bladder tumor patients, they can be divided into different grades, which has important clinical significance in predicting the prognosis of patients for 1 ~ 5 years, but it needs to be further verified by multi-center and large sample clinical trials.
【作者单位】：甘肃省人民医院泌尿外科;
【分类号】：R737.14

【共引文献】